Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glenzocimab as add-on therapy within 4.5 hours after acute ischemic stroke
2021-002148-56Phase 2Completed
- Sponsor
- Acticor Biotech
- Start
- May 2021
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ischemic stroke comparing Glenzocimab + standard of care with Placebo + standard of care (2 arms). Started May 2021; status: completed.
02
Drugs
glenzocimab
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2021-002148-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002148-56.